Research Analysts' Weekly Ratings Updates for Teva Pharmaceutical Industries


Several brokerages have updated their recommendations and price targets on shares of Teva Pharmaceutical Industries in the last few weeks: 2/28/2017 - Teva Pharmaceutical Industries was downgraded by analysts at Argus from a "buy" rating to a "hold" rating. They now have a $31.90 price target on the stock, down previously from $59.35.



from Biotech News